Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.
Separately, Wall Street Zen upgraded Phathom Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, October 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.50.
Check Out Our Latest Stock Report on Phathom Pharmaceuticals
Phathom Pharmaceuticals Price Performance
Shares of PHAT opened at $13.53 on Friday. The business's fifty day moving average price is $12.04 and its 200 day moving average price is $8.64. Phathom Pharmaceuticals has a 12-month low of $2.21 and a 12-month high of $19.50. The stock has a market capitalization of $959.82 million, a PE ratio of -2.86 and a beta of 0.43.
Hedge Funds Weigh In On Phathom Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Phathom Pharmaceuticals in the 2nd quarter worth about $30,000. Ameritas Investment Partners Inc. increased its stake in Phathom Pharmaceuticals by 39.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company's stock worth $41,000 after purchasing an additional 1,216 shares in the last quarter. CWM LLC increased its stake in Phathom Pharmaceuticals by 20,997.1% in the 1st quarter. CWM LLC now owns 7,384 shares of the company's stock worth $46,000 after purchasing an additional 7,349 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Phathom Pharmaceuticals by 71.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company's stock worth $49,000 after purchasing an additional 2,122 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Phathom Pharmaceuticals by 58.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company's stock worth $55,000 after purchasing an additional 2,102 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company's stock.
About Phathom Pharmaceuticals
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
